Matching articles for "Wegovy"
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • May 30, 2022; (Issue 1651)
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a...
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a 5-10% reduction in weight, which has been
associated with a reduction in the risk of developing
type 2 diabetes, hypertension, and dyslipidemia. Diet,
exercise, and behavior modification are the preferred
methods for losing weight, but long-term weight
maintenance can be difficult. Several drugs and
devices are FDA-approved for weight reduction and
maintenance of weight loss.
Comparison Table: Some FDA-Approved Drugs for Weight Management (online only)
The Medical Letter on Drugs and Therapeutics • May 30, 2022; (Issue 1651)
...
View the Comparison Table: Some FDA-Approved Drugs for Weight Management
In Brief: Higher-Dose Semaglutide (Ozempic) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 16, 2022; (Issue 1650)
The FDA has approved a higher-dose injectable
formulation of the long-acting glucagon-like
peptide-1 (GLP-1) receptor agonist semaglutide
(Ozempic) for treatment of type 2 diabetes in adults.
A single SC...
The FDA has approved a higher-dose injectable
formulation of the long-acting glucagon-like
peptide-1 (GLP-1) receptor agonist semaglutide
(Ozempic) for treatment of type 2 diabetes in adults.
A single SC injection of the new 8 mg/3 mL
formulation delivers 2 mg of semaglutide.
Semaglutide (Wegovy) for Weight Loss
The Medical Letter on Drugs and Therapeutics • July 12, 2021; (Issue 1628)
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide, previously approved
by the FDA as Ozempic to treat type 2 diabetes and
to reduce the risk of major adverse cardiovascular
events...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide, previously approved
by the FDA as Ozempic to treat type 2 diabetes and
to reduce the risk of major adverse cardiovascular
events in adults with type 2 diabetes and established
cardiovascular disease, has now been approved in
a higher dose as Wegovy (Novo Nordisk) for chronic
weight management in adults with or without type 2
diabetes who have a body mass index (BMI) ≥30 kg/m2
or a BMI ≥27 kg/m2 and ≥1 weight-related comorbidity
(e.g., hypertension, dyslipidemia). An oral formulation
of semaglutide (Rybelsus) has been available since
2019 for treatment of type 2 diabetes, but it is not
approved for weight management. Liraglutide
(Saxenda), another subcutaneously injected GLP-1
receptor agonist, was approved for chronic weight
management in 2015.